Abstract
This study aimed to investigate the potential role of gut microbiota in the hepatotoxicity of sodium valproate (SVP) and the protective effect of ginsenoside compound K (G-CK) administration against SVP-induced hepatotoxicity in rats. Measurements of 16S rRNA showed that SVP supplementation led to a 140.749- and 248.900-fold increase in the relative abundance of Akkermansia muciniphila (A. muciniphila) and Bifidobacterium pseudolongum (B. pseudolongum), respectively (p < 0.05). The increase in A. muciniphila was almost completely reversed by G-CK treatment. The relative abundance of A. muciniphila was strongly positively correlated with aspartate transaminase (AST) and alanine aminotransferase (ALT) levels (r > 0.78, p < 0.05). The PICRUSt analysis showed that G-CK could inhibit the changes of seven pathways caused by SVP, of which four pathways, including the fatty acid biosynthesis, lipid biosynthesis, glycolysis/gluconeogenesis, and pyruvate metabolism, were found to be negatively correlated with AST and ALT levels (r ≥ 0.70, p < 0.01 or < 0.05). In addition, the glycolysis/gluconeogenesis and pyruvate metabolism were negatively correlated with the relative abundance of A. muciniphila (r > 0.65, p < 0.01 or < 0.05). This alteration of the gut microbiota composition that resulted in observed changes to the glycolysis/gluconeogenesis and pyruvate metabolism may be involved in both the hepatotoxicity of SVP and the protective effect of G-CK administration against SVP-induced hepatotoxicity. Our study provides new evidence linking the gut microbiota with SVP-induced hepatotoxicity.
Introduction
Valproic acid and its derivatives function as effective anticonvulsants. They are also used for the treatment of several other conditions, including bipolar disorder, migraines, neuropathic pain, various forms of headache, Alzheimer's disease, multiple sclerosis, viral infections, and a wide variety of cancers (De Souza and Chatterji, 2015; Mishra et al., 2021; Stakisaitis et al., 2022). However, the potential adverse effects associated with valproic acid and its derivatives have been reported, either as monotherapy or polytherapy with other antiepileptic drugs or antipsychotic drugs (Nanau and Neuman, 2013; Hakami, 2021). The hepatotoxicity of valproic acid and its derivatives is a fatal adverse drug reaction identified as the third most common cause of drug-induced liver fatalities by the World Health Organization (Vidaurre et al., 2017). To find solutions to this outcome from the usage of such drugs, the mechanisms and effective interventions for hepatotoxicity of valproic acid and its derivatives have been a long-term focus for many researchers.
Ginsenoside compound K [20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol; also known by the names M1, compound K, IH901, CK, and G-CK] is a main active metabolite of Panax notoginseng saponins (Kim, 2013). It possesses favorable drug properties according to preclinical and phase I clinical trials (Registration number: ChiCTR-TRC-14004824 and ChiCTR-IPR-15006107) (Chen et al., 2017a,b) and multiple pharmacological activities. These include anticarcinogenic, antiangiogenic, antidiabetic, anti-inflammatory, anti-allergic, antiaging, and neuroprotective and hepatoprotective activities (Yang et al., 2015; Liu et al., 2022). Our previous research has shown that G-CK could alleviate the hepatotoxicity of sodium valproate (SVP) (Zhou et al., 2020a, 2021), while the underlying mechanism is not yet fully understood.
The gastrointestinal tract of a mammal contains a vast, complex, and dynamic consortium of microorganisms known collectively as the gut microbiota, also known as the ‘second genome’ of the human body. It is widely recognized to play an important role in coordinating the healthy and diseased states of the host. Recently, the composition of gut microbiota has been linked to the hepatotoxicity of atrazine (Liu et al., 2021), 1,4-dioxane (Zhou et al., 2020b), difenoconazole (Jiang et al., 2020), geniposide (Li et al., 2019), palmitic acid (Ding et al., 2018), acetaminophen (Gong et al., 2018), tacrine (Yip et al., 2018), N, N-dimethylformamide (Zhang et al., 2017), and PCB126 (Chi et al., 2019). In addition, the gut microbiota has also been reported to mediate the hepatoprotective effects of many forms of interventions (Meng et al., 2018; Yang et al., 2021). The role of gut microbiota presents a new research direction for exploring the mechanisms and effective interventions of drug-induced liver injury.
At present, the relationship between the hepatotoxicity of valproic acid or its derivatives and gut microbiota remains unclear, but valproic acid or SVP has been shown to cause a change in the composition of gut microbiota in rats and enhance or reduce the production of some fatty acids in microorganisms (Cussotto et al., 2019; Poolchanuan et al., 2020). The valproic acid rat model of autism can mimic the microbiome features of autism (Liu et al., 2018). Numerous studies have focused on the role of gut microbiota in the metabolism of ginsenosides to G-CK; however, less is known about the effects of G-CK on gut microbiota. Shao et al. recently reported that the gut microbiota contributes to the anti-colorectal cancer effect of G-CK (Shao et al., 2022). These findings led us to speculate that the hepatotoxicity of valproic acid or its derivatives and the hepatoprotective effect of G-CK may be related to gut microbiota.
Based on the above facts, this study aimed to investigate the effects of SVP either alone or combined with G-CK on gut microbiota composition, the relationship between the changes in gut microbiota composition and SVP-induced hepatotoxicity, and the protective effect of G-CK administration against SVP-induced hepatotoxicity.
Materials and Methods
Drugs and Chemicals
Ginsenoside compound K with 98% purity was provided by Hisun Pharmaceutical Co., Ltd. (Taizhou, China) and was prepared as a suspension in 0.5% sodium carboxymethylcellulose (CMC-Na) for intragastric administration. SVP was obtained from Hunan Xiangzhong Pharmaceutical Co., Ltd. (Shaoyang, China) and was dissolved in physiological saline for intragastric administration. The Stool DNA Isolation Kit was purchased from Qiagen (Shanghai, China).
Animal Experiment
The fecal samples and liver injury-related indices including plasma aspartate transaminase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels were obtained from the control (Con), 500 mg/kg SVP twice daily, and combined 320 mg/kg G-CK once daily, and SVP (G-CK + SVP) groups of a previous study (Zhou et al., 2020a). The animal study was reviewed and approved by the Laboratory Animal Ethics Committee of Servicebio in strict accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications NO. 80-23, revised 1996).
Gut Microbiota Analysis
Total bacterial genomic DNA was extracted from the fecal samples using a stool DNA Isolation Kit, following the manufacturer's instructions. Extracts were then treated with DNase-free RNase to eliminate RNA contaminants. Both the DNA yield and quality were measured by using a NanoDrop spectrophotometer, and the DNA integrity was analyzed by 1% agarose gel electrophoresis. The extracted DNA was amplified using universal primers (515F 5′-GTGYCAGCMGCCGCGGTAA-3′ and 806R 5′-GGACTACNVGGGTWTCTAAT-3′) to obtain the V4 regions of the 16S rRNA gene (Apprill et al., 2015; Parada et al., 2016). The reaction mixtures were set up using 25 μl of PCR Master Mix, 4 μl of each primer (10 μM), 30 ng of template DNA, and added with water up to 50 μl. The reaction parameters were as follows: 98°C pre-denaturation for 3 min, 95°C denaturation for 30 s, 55°C annealing for 45 s, 72°C extension for 45 s, for 40 cycles, followed by a final amplification step of 7 min at 72°C. High-throughput sequencing of amplicons was performed by the BGI technology company (Shenzhen, China) using the Illumina HiSeq 2500 system. Alpha diversity (within sample diversity) and beta diversity (whole community composition/inter-sample diversity) estimates were calculated by using Mothur (version 1.31.2). Alpha diversity indices used were as follows: Chao1, ACE, and Shannon indices. The Euclidean distance and Bray–Curtis matrix at the OTU level were used to explore the beta diversity. Principal components analysis (PCA) and principal coordinate analysis (PCoA) were further used to visualize the beta diversity. The LEfSe analysis was used to screen potential bacterial biomarkers related to the protective effect of G-CK against SVP-induced liver injury. The function of gut microbiota was predicted through the use of the PICRUSt software package. The data presented in the study are deposited in the NCBI repository, accession number PRJNA837380.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism (version 9.0.0) and R studio (version 3.1.1). Data were expressed as means ± SD, except for Chao1, ACE, and Shannon, which were presented as medians and min-to-max values. Alpha diversity was analyzed with Wilcoxon rank-sum tests. Kruskal–Wallis non-parametric test with Benjamini–Hochberg's correction was applied for the statistical analysis of the relative abundance of gut microbiota between groups. Spearman's correlation was carried out to further screen the relationship between gut microbiota and liver injury-related indices. Data with p < 0.05 were considered to have statistical differences.
Results
Gut Microbiota Composition
Alpha-diversity analysis indicated that the values of the Chao1 richness estimator, ACE richness estimator, and the Shannon diversity index showed no significant differences among Con, SVP, and G-CK + SVP groups. The beta diversity (PCA and PCoA) demonstrated clear separation between Con and SVP groups and between SVP and G-CK + SVP groups. These results are presented in Figure 1.
Figure 1
The taxonomic composition of gut bacterial communities in each sample is displayed in Supplementary Figure 1, and the different analyses of relative abundance among groups at the phylum, class, order, family, genus, and species levels are shown in Supplementary Tables 1–6. At the species level, the relative abundance of Akkermansia muciniphila (A. muciniphila), Alistipes indistinctus, Bacteroides acidifaciens (B. acidifaciens), Bacteroides eggerthii, Bifidobacterium pseudolongum (B. pseudolongum), Lactobacillus reuteri (L. reuteri), and Prevotella copri (P. copri) were significantly increased in the SVP group (the ratio of SVP vs. Con: 140.749, 8.217, 2.336, 7.806, 248.900, 0.187, and 0.044). Ginsenoside compound K significantly inhibited changes in the relative abundance of A. muciniphila, B. acidifaciens, L. reuteri, and P. copri caused by SVP (the ratio of G-CK + SVP vs. SVP: 0.007, 0.494, 4.136, and 35.028).
The results of LEfSe analysis also showed that the relative abundance of A. muciniphila and B. pseudolongum were higher in the SVP group than in the Con and G-CK + SVP groups (Figure 2). These results showed that the relative abundance of both A. muciniphila and B. pseudolongum were correlated with the hepatotoxicity of SVP and the protective effect of G-CK.
Figure 2
Correlation Between Gut Microbiota Composition and Indices of Liver Function
To investigate the relationship between gut microbiota and liver injury, Spearman's correlation was carried out on the gut microbiota and indices of the liver function of rats from the SVP group. The results of the LEfSe analysis drew our attention to A. muciniphila and B. pseudolongum. The correlation analysis revealed that A. muciniphila was positively correlated with both plasma AST and ALT levels (Table 1). This implicated A. muciniphila to be involved in modulating the formation of liver injury induced by SVP.
Table 1
| Gut bacteriaa | AST | ALT | ALP | |||
|---|---|---|---|---|---|---|
| r | p | r | p | r | p | |
| Akkermansia muciniphila | 0.8167 | 0.0108 | 0.7833 | 0.0172 | 0.0333 | 0.9484 |
| Bifidobacterium pseudolongum | 0.0714 | 0.8820 | 0.0857 | 0.9194 | 0.1429 | 0.7825 |
Spearman's correlation of gut microbiota and indices of liver function.
LEfSe analysis showed that the relative abundance of Akkermansia muciniphila and Bifidobacterium pseudolongum were higher in the SVP group than in the Con and G-CK + SVP groups. AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Con, control; SVP, sodium valproate (500 mg/kg, twice daily); G-CK, ginsenoside compound K (320 mg/kg, once daily). Bold indicates correlation.
Functional Analysis of Gut Microbiota
Analysis by PICRUSt showed that there were seven overlapped differential pathways between SVP vs. Con and G-CK + SVP vs. SVP. These pathways included fatty acid biosynthesis, lipid biosynthesis, propanoate metabolism, histidine metabolism, glycolysis/gluconeogenesis, pyruvate metabolism, and fructose and mannose metabolism (Figure 3). Following this analysis, four pathways including the fatty acid biosynthesis, lipid biosynthesis, glycolysis/gluconeogenesis, and pyruvate metabolism were found to be negatively correlated with both plasma AST and ALT levels in the SVP group (Table 2). In addition, both the glycolysis/gluconeogenesis and pyruvate metabolism pathways were negatively related to the relative abundance of A. muciniphila in the SVP group (r = −0.7842, p = 0.0098; r = −0.6687, p = 0.0399, respectively). This suggests that the altered levels of glycolysis/gluconeogenesis and pyruvate metabolism likely mediate the role of A. muciniphila in SVP-induced hepatotoxicity and the protective effect of G-CK.
Figure 3
Table 2
| Pathwaysa | AST | ALT | ALP | |||
|---|---|---|---|---|---|---|
| r | p | r | p | r | p | |
| Fatty acid biosynthesis | −0.7000 | 0.0433 | −0.7500 | 0.0255 | −0.1879 | 0.6073 |
| Lipid biosynthesis | −0.7000 | 0.0433 | −0.7500 | 0.0255 | −0.2606 | 0.4697 |
| Propanoate metabolism | −0.4167 | 0.2696 | −0.1667 | 0.6777 | −0.0667 | 0.8651 |
| Histidine metabolism | 0.2500 | 0.5206 | 0.1333 | 0.7435 | −0.2121 | 0.5603 |
| Glycolysis/gluconeogenesis | −0.8667 | 0.0045 | −0.8333 | 0.0083 | 0.0182 | 0.9730 |
| Pyruvate metabolism | −0.8167 | 0.0108 | −0.8000 | 0.0138 | −0.1152 | 0.7589 |
| Fructose and mannose metabolism | 0.2000 | 0.6134 | 0.4000 | 0.2912 | 0.0424 | 0.9184 |
Spearman's correlation of pathways and indices of liver function.
Overlapped differential pathways between SVP vs. Con and G-CK + SVP vs. SVP estimated. AST, aspartate transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Con, control; SVP, sodium valproate (500 mg/kg, twice daily); G-CK, ginsenoside compound K (320 mg/kg, once daily). Bold indicates correlation.
Discussion
This study found that SVP caused gut microbiota dysbiosis in the rat, while G-CK could partially ameliorate these changes. At the species level, SVP induced an extremely high accumulation of both A. muciniphila and B. pseudolongum, and the increased A. muciniphila was almost completely reversed by treatment with G-CK. The relative abundance of A. muciniphila was strongly positively correlated with AST and ALT levels. PICRUSt analysis showed that there were seven overlapped differential pathways between SVP vs. Con and G-CK + SVP vs. SVP, of which four pathways including fatty acid biosynthesis, lipid biosynthesis, glycolysis/gluconeogenesis, and pyruvate metabolism were found to be negatively correlated with AST and ALT levels. In addition, the glycolysis/gluconeogenesis and pyruvate metabolism were negatively related to the relative abundance of A. muciniphila.
Akkermansia muciniphila, an intestinal symbiont colonizing in the mucosal layer, can use mucin as its sole carbon, nitrogen, and energy source. This feature renders it to be a promising candidate in probiotic formulations, as it is known to have an important value in metabolic modulation, immune regulation, and protection of gut health (Zhai et al., 2019; Zhang et al., 2019). Although many studies have shown the beneficial effects of A. muciniphila, some researchers have taken the opposite view of the species. For instance, alcohol-treated mice have shown higher intestinal levels of A. muciniphila (Yan et al., 2011). Additionally, in both specific-pathogen-free and germ-free IL10−/− mice, A. muciniphila administration was sufficient for promoting intestinal inflammation (Seregin et al., 2017). A diet including heme has also been shown to lead to a damaged gut epithelium, compensatory hyperproliferation, and an 8-fold increase in A. muciniphila. Broad-spectrum antibiotics were able to reduce the abundance of A. muciniphila more than 1,000-fold, and this was accompanied by eliminating the observed hyperproliferation phenotype (Ijssennagger et al., 2015). High L-carnitine supplementation has also been shown to induce the accumulation of A. muciniphila, and the relative abundance of A. muciniphila was strongly positively correlated with AST, IL-1, TNF-α, TNF-β, and MDA levels in male mice (Wu et al., 2020). In this study, we observed that the repeated oral gavage of SVP induced a 140-fold elevation in the relative abundance of A. muciniphila, which was almost completely reversed by the administration of G-CK. The relative abundance of A. muciniphila was strongly positively correlated with AST and ALT levels. This suggests that decreasing the population level of A. muciniphila might mediate the protective effects of G-CK against the hepatotoxicity of SVP, and thus researchers should give further recognition to the potentially adverse effects of A. muciniphila.
Furthermore, the functional pathways of gut microbiota were disturbed by SVP exposures. Seven of the changed pathways caused by SVP, including fatty acid biosynthesis, lipid biosynthesis, propanoate metabolism, histidine metabolism, glycolysis/gluconeogenesis, pyruvate metabolism, and fructose and mannose metabolism, were significantly inhibited by G-CK. Meanwhile, the fatty acid biosynthesis, lipid biosynthesis, glycolysis/gluconeogenesis, and pyruvate metabolism were negatively correlated with both AST and ALT levels. The glycolysis/gluconeogenesis and pyruvate metabolism were negatively correlated with the relative abundance of A. muciniphila. Pyruvate metabolism is known to be closely related to glycolysis/gluconeogenesis with pyruvate as the main connecting node. It was reported that both valproic acid and SVP could increase the liver tissue and blood concentrations of pyruvate and strongly inhibit its oxidation (Daniels et al., 2004; Huo et al., 2014; Kudin et al., 2017). Pyruvate oxidation defects are among the most frequent causes of deficiencies in mitochondrial energy metabolism, thus an important feature of classical mitochondrial diseases (Sperl et al., 2015). Mitochondrial dysfunction is a well-known mechanism of SVP-induced hepatotoxicity (Ramachandran et al., 2018). Based on this, we speculate that the decrease in pyruvate metabolism mediated by the increase in A. muciniphila might be involved in the hepatotoxicity of SVP. Unfortunately, we did not measure the concentrations of pyruvate in plasma and fecal samples due to sample insufficiency. We have designed experiments to further study the role of A. muciniphila in the hepatotoxicity of SVP, which has been supported by the China Postdoctoral Science Foundation. This will provide new insights into the mechanisms, early warning signs, and possible prevention strategies for SVP-induced hepatotoxicity.
In conclusion, SVP-induced hepatotoxicity was related to gut microbiota dysbiosis, namely, the increased relative abundance of A. muciniphila and decreased glycolysis/gluconeogenesis and pyruvate metabolism pathways. Ginsenoside compound K could significantly improve the outcomes caused by SVP exposure. The results in this study suggest that the altered levels of A. muciniphila resulted in changes in glycolysis/gluconeogenesis and pyruvate metabolism, and this may modulate the hepatotoxicity of SVP and the protective effect of G-CK administration against SVP-induced hepatotoxicity.
Funding
This study was supported by the China Postdoctoral Science Foundation (No. 2021M702910), the Key R&D Programs of Hunan Province (No. 2019SK2241), the Innovation and Entrepreneurship Investment Project in Hunan Province (No. 2019GK5020), the International Scientific and Technological Innovation Cooperation Base for Bioanalysis of Complex Matrix Samples in Hunan Province (No. 2019CB1014), and the Science and Technology Project of Changsha (No. kh1902002).
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: NCBI—PRJNA837380.
Ethics statement
The animal study was reviewed and approved by Laboratory Animal Ethics Committee of Servicebio.
Author contributions
LZ, LC, and DO designed the study. LZ performed the experiments, analyzed the data, and drafted the manuscript. LZ, XZ, JL, LC, and DO revised the manuscript. All authors read and approved the final manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2022.936585/full#supplementary-material
Supplementary Figure 1Relative abundance of gut microbiota in each sample at phylum, class, order, family, genus, and species levels, n = 10 in each group. Con, control; SVP, sodium valproate (500 mg/kg, twice daily); G-CK, ginsenoside compound K (320 mg/kg, once daily).
Supplementary Table 1Statistics values for relative abundance of bacterial phylum.
Supplementary Table 2Statistics values for relative abundance of bacterial class.
Supplementary Table 3Statistics values for relative abundance of bacterial order.
Supplementary Table 4Statistics values for relative abundance of bacterial family.
Supplementary Table 5Statistics values for relative abundance of bacterial genus.
Supplementary Table 6Statistics values for relative abundance of bacterial species.
References
1
ApprillA.McnallyS.ParsonsR.WeberL. (2015). Minor revision to V4 region SSU rRNA 806R gene primer greatly increases detection of SAR11 bacterioplankton. Aquatic. Microbial. Ecol.75, 2. 10.3354/ame01753
2
ChenL.ZhouL.HuangJ.WangY.YangG.TanZ.et al. (2017a). Single- and multiple-dose trials to determine the pharmacokinetics, safety, tolerability, and sex effect of oral ginsenoside compound k in healthy chinese volunteers. Front. Pharmacol.8, 965. 10.3389/fphar.2017.00965
3
ChenL.ZhouL.WangY.YangG.HuangJ.TanZ.et al. (2017b). Food and sex-related impacts on the pharmacokinetics of a single-dose of ginsenoside compound K in healthy subjects. Front. Pharmacol.8, 636. 10.3389/fphar.2017.00636
4
ChiY.LinY.LuY.HuangQ.YeG.DongS. (2019). Gut microbiota dysbiosis correlates with a low-dose PCB126-induced dyslipidemia and non-alcoholic fatty liver disease. Sci. Total Environ.653, 274–282. 10.1016/j.scitotenv.2018.10.387
5
CussottoS.StrainC. R.FouhyF.StrainR. G.PetersonV. L.ClarkeG.et al. (2019). Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. Psychopharmacology (Berl)236, 1671–1685. 10.1007/s00213-018-5006-5
6
DanielsT.GallagherM.TremblayG.RodgersR. L. (2004). Effects of valproic acid on cardiac metabolism. Can. J. Physiol. Pharmacol.82, 927–933. 10.1139/y04-096
7
De SouzaC.ChatterjiB. P. (2015). HDAC inhibitors as novel anti-cancer therapeutics. Recent. Pat. Anticancer Drug Discov.10, 145–162. 10.2174/1574892810666150317144511
8
DingQ.ZhangZ.RanC.HeS.YangY.DuZ.et al. (2018). The hepatotoxicity of palmitic acid in zebrafish involves the intestinal microbiota. J. Nutr.148, 1217–1228. 10.1093/jn/nxy084
9
GongS.LanT.ZengL.LuoH.YangX.LiN.et al. (2018). Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J. Hepatol.69, 51–59. 10.1016/j.jhep.2018.02.024
10
HakamiT. (2021). Neuropharmacology of antiseizure drugs. Neuropsychopharmacol. Rep.41, 336–351. 10.1002/npr2.12196
11
HuoT.ChenX.LuX.QuL.LiuY.CaiS. (2014). An effective assessment of valproate sodium-induced hepatotoxicity with UPLC-MS and (1)HNMR-based metabonomics approach. J. Chromatogr. B Anal. Technol. Biomed. Life Sci.969, 109–116. 10.1016/j.jchromb.2014.08.011
12
IjssennaggerN.BelzerC.HooiveldG. J.DekkerJ.van MilS. W.MullerM.et al. (2015). Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc. Natl. Acad. Sci. U S A112, 10038–10043. 10.1073/pnas.1507645112
13
JiangJ.ChenL.WuS.LvL.LiuX.WangQ.et al. (2020). Effects of difenoconazole on hepatotoxicity, lipid metabolism and gut microbiota in zebrafish (Danio rerio). Environ. Pollut.265, 114844. 10.1016/j.envpol.2020.114844
14
KimH. K. (2013). Pharmacokinetics of ginsenoside Rb1 and its metabolite compound K after oral administration of Korean Red Ginseng extract. J. Ginseng. Res.37, 451–456. 10.5142/jgr.2013.37.451
15
KudinA. P.MawasiH.EisenkraftA.ElgerC. E.BialerM.KunzW. S. (2017). Mitochondrial liver toxicity of valproic acid and its acid derivatives is related to inhibition of and#945;-lipoamide dehydrogenase. Int. J. Mol. Sci.18, 9. 10.3390/ijms18091912
16
LiY.PanH.LiX.JiangN.HuangL.LuY.et al. (2019). Role of intestinal microbiota-mediated genipin dialdehyde intermediate formation in geniposide-induced hepatotoxicity in rats. Toxicol. Appl. Pharmacol.377, 114624. 10.1016/j.taap.2019.114624
17
LiuB.ZengQ.ChenH.LiaoJ.BaiY.HanQ.et al. (2021). The hepatotoxicity of altrazine exposure in mice involves the intestinal microbiota. Chemosphere272, 129572. 10.1016/j.chemosphere.2021.129572
18
LiuF.Horton-SparksK.HullV.LiR. W.Martinez-CerdenoV. (2018). The valproic acid rat model of autism presents with gut bacterial dysbiosis similar to that in human autism. Mol. Autism9, 61. 10.1186/s13229-018-0251-3
19
LiuT.ZhuL.WangL. (2022). A narrative review of the pharmacology of ginsenoside compound K. Ann. Transl. Med. 10, 234. 10.21037/atm-22-501
20
MengX.LiS.LiY.GanR. Y.LiH. B. (2018). Gut microbiota's relationship with liver disease and role in hepatoprotection by dietary natural products and probiotics. Nutrients10, 1457. 10.3390/nu10101457
21
MishraM. K.KukalS.PaulP. R.BoraS.SinghA.KukretiS.et al. (2021). Insights into structural modifications of valproic acid and their pharmacological profile. Molecules27, 104. 10.3390/molecules27010104
22
NanauR. M.NeumanM. G. (2013). Adverse drug reactions induced by valproic acid. Clin. Biochem.46, 1323–1338. 10.1016/j.clinbiochem.2013.06.012
23
ParadaA. E.NeedhamD. M.FuhrmanJ. A. (2016). Every base matters: assessing small subunit rRNA primers for marine microbiomes with mock communities, time series and global field samples. Environ. Microbiol.18, 1403–1414. 10.1111/1462-2920.13023
24
PoolchanuanP.UnagulP.ThongnestS.WiyakruttaS.NgamrojanavanichN.MahidolC.et al. (2020). An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms. Sci. Rep.10, 9300. 10.1038/s41598-020-66251-y
25
RamachandranA.VisschersR. G. J.DuanL.AkakpoJ. Y.JaeschkeH. (2018). Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives. J. Clin. Transl. Res.4, 75–100. 10.18053/jctres.04.201801.005
26
SereginS. S.GolovchenkoN.SchafB.ChenJ.PudloN. A.MitchellJ.et al. (2017). NLRP6 Protects Il10(-/-) mice from colitis by limiting colonization of akkermansia muciniphila. Cell Rep.19, 733–745. 10.1016/j.celrep.2017.03.080
27
ShaoL.GuoY. P.WangL.ChenM. Y.ZhangW.DengS.et al. (2022). Effects of ginsenoside compound K on colitis-associated colorectal cancer and gut microbiota profiles in mice. Ann. Transl. Med.10, 408. 10.21037/atm-22-793
28
SperlW.FleurenL.FreisingerP.HaackT. B.RibesA.FeichtingerR. G.et al. (2015). The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders. J. Inherit. Metab. Dis.38, 391–403. 10.1007/s10545-014-9787-3
29
StakisaitisD.KapociusL.ValanciuteA.BalnyteI.TamosuitisT.VaitkeviciusA.et al. (2022). SARS-CoV-2 infection, sex-related differences, and a possible personalized treatment approach with valproic acid: a review. Biomedicines10, 962. 10.3390/biomedicines10050962
30
VidaurreJ.GedelaS.YaroszS. (2017). Antiepileptic drugs and liver disease. Pediatr. Neurol.77, 23–36. 10.1016/j.pediatrneurol.2017.09.013
31
WuQ.ZhangX.ZhaoY.YangX. (2020). High l-carnitine ingestion impairs liver function by disordering gut bacteria composition in mice. J. Agric. Food Chem.68, 5707–5714. 10.1021/acs.jafc.9b08313
32
YanA. W.FoutsD. E.BrandlJ.StarkelP.TorralbaM.SchottE.et al. (2011). Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology53, 96–105. 10.1002/hep.24018
33
YangX. D.YangY. Y.OuyangD. S.YangG. P. (2015). A review of biotransformation and pharmacology of ginsenoside compound K. Fitoterapia100, 208–220. 10.1016/j.fitote.2014.11.019
34
YangX. F.LuM.YouL.GenH.YuanL.TianT.et al. (2021). Herbal therapy for ameliorating non-alcoholic fatty liver disease via rebuilding the intestinal microecology. Chin. Med.16, 62. 10.1186/s13020-021-00470-x
35
YipL. Y.AwC. C.LeeS. H.HongY. S.KuH. C.XuW. H.et al. (2018). The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology67, 282–295. 10.1002/hep.29327
36
ZhaiQ.FengS.ArjanN.ChenW. (2019). A next generation probiotic, Akkermansia muciniphila. Crit. Rev. Food Sci. Nutr.59, 3227–3236. 10.1080/10408398.2018.1517725
37
ZhangM.ZhengM.WuZ.GuanM.LiuS.ZhaoW.et al. (2017). Alteration of gut microbial community after N,N-Dimethylformamide exposure. J. Toxicol. Sci.42, 241–250. 10.2131/jts.42.241
38
ZhangT.LiQ.ChengL.BuchH.ZhangF. (2019). Akkermansia muciniphila is a promising probiotic. Microb. Biotechnol.12, 1109–1125. 10.1111/1751-7915.13410
39
ZhouL.ChenL.ZengX.LiaoJ.OuyangD. (2020a). Ginsenoside compound K alleviates sodium valproate-induced hepatotoxicity in rats via antioxidant effect, regulation of peroxisome pathway and iron homeostasis. Toxicol. Appl. Pharmacol.386, 114829. 10.1016/j.taap.2019.114829
40
ZhouL.ZengX.RaoT.TanZ.ZhouG.OuyangD.et al. (2021). Evaluating the protective effects of individual or combined ginsenoside compound K and the downregulation of soluble epoxide hydrolase expression against sodium valproate-induced liver cell damage. Toxicol. Appl. Pharmacol.422, 115555. 10.1016/j.taap.2021.115555
41
ZhouQ.JiangL.QiuJ.PanY.SwandaR. V.ShiP.et al. (2020b). Oral exposure to 1,4-dioxane induces hepatic inflammation in mice: the potential promoting effect of the gut microbiome. Environ. Sci. Technol.54, 10149–10158. 10.1021/acs.est.0c01543
Summary
Keywords
sodium valproate, ginsenoside compound K, hepatotoxicity, gut microbiota, Akkermansia muciniphila
Citation
Zhou L, Zeng X, Liao J, Chen L and Ouyang D (2022) Gut Microbiota Modulates the Protective Role of Ginsenoside Compound K Against Sodium Valproate-Induced Hepatotoxicity in Rat. Front. Microbiol. 13:936585. doi: 10.3389/fmicb.2022.936585
Received
13 May 2022
Accepted
13 June 2022
Published
07 July 2022
Volume
13 - 2022
Edited by
Lucia Grenga, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), France
Reviewed by
Jiachao Zhang, Hunan Agricultural University, China; Michel Geovanni Santiago Martinez, The Pennsylvania State University (PSU), United States
Updates
Copyright
© 2022 Zhou, Zeng, Liao, Chen and Ouyang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lulu Chen lulu.chen@duxact.comDongsheng Ouyang 801940@csu.edu.cn
This article was submitted to Systems Microbiology, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.